Shane Brisbin
Directeur/Membre du Conseil chez Alzeca Biosciences, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Carlo Giovanni Medici | M | - |
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | - |
Ananth Annapragada | M | - |
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | 12 ans |
Peter Werth | M | 85 |
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | 7 ans |
Stephen Cook | M | 74 |
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | - |
Navneet Puri | M | - |
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | 7 ans |
Scott W. Atlas | M | - |
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 6 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Shane Brisbin
- Réseau Personnel